Total Payments
$168,356
2024 Payments
$11,069
Companies
55
Transactions
1,638
Medicare Patients
6,173
Medicare Billing
$1.5M
Payment Breakdown by Category
Other$87,471 (52.0%)
Food & Beverage$29,499 (17.5%)
Travel$17,736 (10.5%)
Research$17,390 (10.3%)
Consulting$15,846 (9.4%)
Education$316.89 (0.2%)
Gifts$96.76 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $71,300 | 41 | 42.4% |
| Food and Beverage | $29,499 | 1,428 | 17.5% |
| Travel and Lodging | $17,736 | 76 | 10.5% |
| Unspecified | $17,390 | 14 | 10.3% |
| Honoraria | $16,172 | 6 | 9.6% |
| Consulting Fee | $15,846 | 9 | 9.4% |
| Education | $316.89 | 25 | 0.2% |
| Gift | $96.76 | 39 | 0.1% |
Payments by Type
General
$150,966
1,624 transactions
Research
$17,390
14 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $43,069 | 142 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $23,700 | 194 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $23,285 | 100 | $0 (2024) |
| Horizon Therapeutics plc | $20,585 | 37 | $0 (2023) |
| Novo Nordisk AS | $17,390 | 14 | $0 (2021) |
| Amgen Inc. | $10,214 | 84 | $0 (2024) |
| Corcept Therapeutics | $8,433 | 69 | $0 (2024) |
| Lilly USA, LLC | $7,300 | 191 | $0 (2024) |
| Novo Nordisk Inc | $3,323 | 234 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $2,011 | 79 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,069 | 125 | Amgen Inc. ($8,865) |
| 2023 | $22,149 | 189 | Horizon Therapeutics plc ($18,918) |
| 2022 | $4,928 | 236 | Horizon Therapeutics plc ($1,497) |
| 2021 | $12,938 | 180 | Novo Nordisk AS ($9,510) |
| 2020 | $6,431 | 172 | Corcept Therapeutics ($3,413) |
| 2019 | $19,845 | 187 | Novo Nordisk AS ($7,880) |
| 2018 | $30,627 | 214 | Janssen Pharmaceuticals, Inc ($12,104) |
| 2017 | $60,369 | 335 | Janssen Pharmaceuticals, Inc ($25,309) |
All Payment Transactions
1,638 individual payment records from CMS Open Payments — Page 1 of 66
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.39 | General |
| Category: DIABETES | ||||||
| 12/23/2024 | Antares Pharma, Inc. | XYOSTED (Drug) | Food and Beverage | In-kind items and services | $24.71 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 12/12/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $11.62 | General |
| Category: Bone Health | ||||||
| 12/12/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $10.49 | General |
| 12/09/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $20.36 | General |
| Category: Cardio-renal | ||||||
| 12/09/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.23 | General |
| Category: Diabetes | ||||||
| 11/25/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $19.01 | General |
| Category: Cardio-renal | ||||||
| 11/15/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $20.31 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 11/14/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $33.02 | General |
| Category: DIABETES | ||||||
| 11/14/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $13.29 | General |
| Category: Bone Health | ||||||
| 11/05/2024 | Antares Pharma, Inc. | XYOSTED (Drug) | Food and Beverage | In-kind items and services | $24.65 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 11/01/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $22.83 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 10/21/2024 | Antares Pharma, Inc. | XYOSTED (Drug) | Food and Beverage | In-kind items and services | $24.79 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 10/18/2024 | BETA BIONICS, INC. | iLet Bionic Pancreas (Device), iLet Bionic Pancreas, iLet Bionic Pancreas | Food and Beverage | In-kind items and services | $27.37 | General |
| Category: Automated insulin delivery system | ||||||
| 10/10/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $34.94 | General |
| Category: Cardiology | ||||||
| 10/09/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $31.49 | General |
| Category: Diabetes | ||||||
| 10/08/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Food and Beverage | In-kind items and services | $34.65 | General |
| Category: Rare Disease | ||||||
| 10/08/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $28.09 | General |
| Category: Cardio-renal | ||||||
| 10/02/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $24.22 | General |
| Category: Diabetes | ||||||
| 09/26/2024 | Antares Pharma, Inc. | XYOSTED (Drug) | Food and Beverage | In-kind items and services | $24.38 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 09/24/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $14.87 | General |
| 09/20/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $12.36 | General |
| Category: Diabetes | ||||||
| 09/12/2024 | Antares Pharma, Inc. | XYOSTED (Drug) | Food and Beverage | In-kind items and services | $24.96 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 09/11/2024 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $17.85 | General |
| 08/30/2024 | Lilly USA, LLC | JARDIANCE (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $26.23 | General |
| Category: Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| NN9535-4416 | Novo Nordisk AS | $17,390 | 14 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 1,627 | 16,530 | $1.1M | $382,939 |
| 2022 | 15 | 1,749 | 29,061 | $1.5M | $499,319 |
| 2021 | 12 | 1,481 | 22,422 | $914,730 | $416,077 |
| 2020 | 12 | 1,316 | 7,562 | $570,675 | $230,362 |
Total Patients
6,173
Total Services
75,575
Medicare Billing
$1.5M
Procedure Codes
53
All Medicare Procedures & Services
53 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 59 | 4,382 | $175,280 | $81,023 | 46.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 474 | 727 | $219,460 | $79,958 | 36.4% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2023 | 17 | 9,240 | $184,800 | $73,637 | 39.8% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 204 | 1,127 | $236,670 | $62,171 | 26.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 208 | 208 | $83,200 | $27,478 | 33.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 266 | 325 | $91,000 | $24,539 | 27.0% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2023 | 118 | 126 | $39,939 | $13,628 | 34.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 32 | 32 | $18,377 | $5,861 | 31.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 20 | 28 | $8,023 | $3,910 | 48.7% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 77 | 119 | $14,118 | $3,292 | 23.3% |
| 10005 | Fine needle aspiration biopsy using ultrasound guidance, first growth | Office | 2023 | 24 | 27 | $12,960 | $2,690 | 20.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 29 | 42 | $8,400 | $2,003 | 23.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 81 | 129 | $5,805 | $1,685 | 29.0% |
| 95249 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin | Office | 2023 | 18 | 18 | $1,800 | $1,062 | 59.0% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2022 | 24 | 19,740 | $394,800 | $146,900 | 37.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 80 | 6,360 | $254,400 | $108,635 | 42.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 547 | 1,044 | $334,080 | $105,323 | 31.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 284 | 428 | $119,840 | $31,254 | 26.1% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 93 | 491 | $103,110 | $27,495 | 26.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 100 | 127 | $44,661 | $18,393 | 41.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 91 | 91 | $56,784 | $16,242 | 28.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 120 | 120 | $48,000 | $14,932 | 31.1% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2022 | 94 | 97 | $30,710 | $9,872 | 32.1% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 105 | 233 | $27,879 | $6,738 | 24.2% |
| 95250 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | Office | 2022 | 26 | 29 | $8,569 | $4,355 | 50.8% |
About Dr. Do-Eun Lee, MD
Dr. Do-Eun Lee, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Napa, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1346339652.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Do-Eun Lee, MD has received a total of $168,356 in payments from pharmaceutical and medical device companies, with $11,069 received in 2024. These payments were reported across 1,638 transactions from 55 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($71,300).
As a Medicare-enrolled provider, Lee has provided services to 6,173 Medicare beneficiaries, totaling 75,575 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 53 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Napa, CA
- Active Since 10/12/2006
- Last Updated 06/23/2009
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1346339652
Products in Payments
- INVOKANA (Drug) $43,214
- JARDIANCE (Drug) $28,029
- TEPEZZA (Drug) $20,561
- Ozempic (Drug) $18,935
- SOLIQUA (Drug) $13,705
- TOUJEO (Drug) $8,887
- TEPEZZA (Biological) $8,717
- Korlym (Drug) $8,433
- FARXIGA (Drug) $1,681
- Omnipod (Device) $1,339
- Tymlos (Biological) $1,002
- TRULICITY (Drug) $965.12
- EVENITY (Biological) $883.15
- AFREZZA (Drug) $708.67
- HUMULIN (Drug) $538.67
- MOUNJARO (Drug) $510.72
- NATPARA (Drug) $399.82
- Repatha (Biological) $383.94
- BAQSIMI (Drug) $374.71
- Kerendia (Drug) $370.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.